# Nurix Therapeutics, Inc. (NRIX) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Nurix Therapeutics, Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/NRIX/mda/fy2025/): filed 2026-01-28; accession 0001549595-26-000016 (https://www.sec.gov/Archives/edgar/data/1549595/000154959526000016/nrix-20251130.htm); latest 10-K
- [FY 2024 MD&A](/company/NRIX/mda/fy2024/): filed 2025-01-28; accession 0001549595-25-000016 (https://www.sec.gov/Archives/edgar/data/1549595/000154959525000016/nrix-20241130.htm)
- [FY 2023 MD&A](/company/NRIX/mda/fy2023/): filed 2024-02-15; accession 0001549595-24-000025 (https://www.sec.gov/Archives/edgar/data/1549595/000154959524000025/nrix-20231130.htm)
- [FY 2022 MD&A](/company/NRIX/mda/fy2022/): filed 2023-02-09; accession 0001549595-23-000021 (https://www.sec.gov/Archives/edgar/data/1549595/000154959523000021/nrix-20221130.htm)
- [FY 2021 MD&A](/company/NRIX/mda/fy2021/): filed 2022-01-28; accession 0001564590-22-003007 (https://www.sec.gov/Archives/edgar/data/1549595/000156459022003007/nrix-10k_20211130.htm)

Back to /company/NRIX/